Invokana Linked to Heart Attack, Kidney Problems, and Ketoacidosis

If you have suffered a heart attack, other cardiovascular problems, kidney damage or ketoacidosis while taking Invokana (canagliflozin) or Invokamet for Type 2 diabetes, your medication may be the cause. Invokana was approved by the U.S. Food and Drug Administration (FDA) in March 2013, to treat Type 2 diabetes. It was the first in a new class of diabetes medication called sodium-glucose co-transporter 2 (SGLT2) inhibitor. If you have been harmed by Invokana or lost a loved one to the side effects of this drug, you may be able to recover compensation based on the drug company’s failure to warn physicians and patients about the dangers.

Invokana Injuries

Invokana users have suffered injuries including:

Diabetic ketoacidosis

Kidney failure or kidney damage serious enough to require transplant

Abnormal weight loss

Urinary tract infections

Yeast infections

When Invokana was approved by the FDA it was in spite of concerns about cardiovascular risks including the risk of stroke. AS part of approval, the FDA required Invokana maker, Janssen Pharmaceuticals, to conduct a post-market study of the cardiovascular risks called Canagliflozin Cardiovascular Assessment Study (CANVAS). The study is to measure the risk of major cardiovascular events including:

Cardiovascular death

Nonfatal myocardial infarction

Nonfatal stroke

No Recall Yet

Invokana has not been recalled, but that is no indication of its safety. One a drug is approved, it can take years of injuries and deaths before any kind of recall is issued, and even then it is usually to update the safety warnings on the label. Withdrawal of a dangerous drug is very rare.

Share this:

Related

About US Recall News

US Recall News provides recall news and information to the United States general public. Find all of the latest drug, food, products, and vehicle recall news as reported by U.S. government agencies and more.